Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 2/2014

Open Access 01-03-2014 | Viewpoint

How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women

Authors: Zhimin Zhang, Yangna Ou, Zhifeng Sheng, Eryuan Liao

Published in: Endocrine | Issue 2/2014

Login to get access

Abstract

The FRAX tool has been used to determine possible thresholds for therapeutic intervention; however, there are no FRAX-based intervention thresholds available for China, we proposed that the 10-year probability of major osteoporotic fracture and hip fracture of about 4.0 and 1.3 %, respectively, may be acceptable intervention thresholds for central south Chinese postmenopausal women.
Literature
1.
J.A. Kanis, on behalf of the World Health Organization Scientific Group, Assessment of osteoporosis at the primary healthcare level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK, (2008)
2.
J.A. Kanis, E.V. McClosky, H. Johansson, O. Strom, F. Borgstrom, A. Oden, National Osteoporosis Guideline Group, Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395–1408 (2008)PubMedCrossRef
3.
K. Siminoski, W.D. Leslie, H. Frame, A. Hodsman, R.G. Josse, A. Khan, B.C. Lentle, J. Levesque, D.J. Lyons, G. Tarulli, J.P. Brown, Recommendations for bone mineral density reporting in Canada: a shift to absolute fracture risk assessment. J Clin Densitom 10, 120–123 (2007)PubMedCrossRef
4.
S. Fujiwara, T. Nakamura, H. Orimo, T. Hosoi, I. Gorai, A. Oden, H. Johansson, J.A. Kanis, Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos. Int. 19, 429–448 (2008)PubMedCentralPubMedCrossRef
5.
A.A. Kurth, J. Pfeilschifter, Diagnosis and treatment of postmenopausal osteoporosis and osteoporosis in men. German guidelines update 2006. Orthopade 36, 683–690 (2007)PubMedCrossRef
6.
B. Awson-Hughes, A.N. Tosteson, L.J. 3rd Melton, S. Baim, M.J. Favus, S. Khosla, R.L. Lindsay, Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos. Int. 19, 449–458 (2008)CrossRef
7.
8.
J.A. Kanis, E.V. McClosky, H. Johansson, A. Oden, Approaches to the targeting of treatment for osteoporosis. Nat. Rev. Rheumatol. 5, 425–431 (2009)PubMedCrossRef
9.
Royal College of Physicians, Osteoporosis: Clinical Guidelines for the Prevention and Treatment (Royal College of Physicians, London, 1999)
10.
Royal College of Physicians and Bone and Tooth Society of Great Britain, Update on Pharmacological Interventions and an Algorithm for Management (Royal College of Physicians, London, 2000)
11.
Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians, Glucocorticoid Induced Osteoporosis: Guidelines on Prevention and Treatment (Royal College of Physicians, London, 2002)
12.
J.A. Kanis, J. Adams, F. Borgström, C. Cooper, B. Jönsson, D. Preedy, P. Selby, J. Compston, The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42, 4–15 (2008)PubMedCrossRef
13.
E. Czerwinski, J.E. Badurski, E. Marcinowska-suchowierska, J. Osieleniec, Current understanding of osteoporosis according to the position of the World Health Organization (WHO) and International Osteoporosis Foundation. Ortop. Traumatol. Rehabil. 9, 337–356 (2007)PubMed
14.
S.W. Tsang, A.W. Kung, J.A. Kanis, H. Johansson, A. Oden, Ten-year fracture probability in Hong Kong southern Chinese according to age and BMD femoral neck T-scores. Osteoporos. Int. 20, 1939–1945 (2009)PubMedCrossRef
15.
K. Lippuner, H. Johansson, J.A. Kanis, R. Rizzoli, Remaining lifetime and absolute 10-year probabilities of osteoporotic fracture in Swiss men and women. Osteoporos. Int. 20, 1131–1140 (2009)PubMedCrossRef
16.
A.N. Tosteson, L.J. 3rd Melton, B. Dawson-Hughes, S. Baim, M.J. Favus, S. Khosla, R.L. Lindsay, National Osteoporosis Foundation Guide Committee, Cost-effective osteoporosis treatment thresholds: the United states perspective. Osteoporos. Int. 19, 437–447 (2008)PubMedCentralPubMedCrossRef
17.
National Osteoporosis Foundation (NOF), Physician’s Guide to Prevention and Treatment of Osteoporosis (National Osteoporosis Foundation, Washington, 2003)
18.
S. Lekamwasam, Application of FRAX Model to Sri Lankan postmenopausal women. J Clin Densitom 13, 51–55 (2010)PubMedCrossRef
19.
A.W. Kung, K.K. Lee, A.Y. Ho, G. Tang, K.D. Luk, Ten-year risk of osteoporotic fractures in postmenopausal Chinese women according to clinical risk factors and BMD T-scores: a prospective study. J. Bone Miner. Res. 22, 1080–1087 (2007)PubMedCrossRef
20.
A.W. Kwok, J.C. Leung, A.Y. Chan AY, B.S. Au, E.M. Lau, H. Yurianto, P. Yuktanandana, N. Yoshimura, S. Muraki, H. Oka, T. Akune, P.C. Leung, Prevalence of vertebral fracture in Asian men and women: comparison between Hong Kong, Thailand, Indonesia and Japan. Public Health 126, 523–531 (2012)PubMedCrossRef
21.
Z. Zhang, X. Shen, H. Zhang, S. Li, H. Zhou, X. Wu, Z. Sheng, E. Liao, The relationship between body composition and fracture risk using the FRAX model in central south Chinese postmenopausal women. Clin. Endocrinol. (Oxf) 77, 524–530 (2012)CrossRef
Metadata
Title
How to decide intervention thresholds based on FRAX in central south Chinese postmenopausal women
Authors
Zhimin Zhang
Yangna Ou
Zhifeng Sheng
Eryuan Liao
Publication date
01-03-2014
Publisher
Springer US
Published in
Endocrine / Issue 2/2014
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0076-y

Other articles of this Issue 2/2014

Endocrine 2/2014 Go to the issue

Original Article

Effect of combined therapy of human Wharton’s jelly-derived mesenchymal stem cells from umbilical cord with sitagliptin in type 2 diabetic rats

Endocrine Imaging

Occult pyogenic liver abscess in an adolescent with type 2 diabetes

Letter to the Editor

Pituitary apoplexy in T3 thyrotoxicosis

Original Article

Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population

Original article

BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto’s thyroiditis is a reliable assay

Original Article

MicroRNA-17-92 cluster regulates osteoblast proliferation and differentiation

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24 to hear Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits